295 related articles for article (PubMed ID: 11477176)
1. A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients.
Hryszko T; Malyszko J; Malyszko JS; Brzosko S; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 2001 Aug; 16(8):1692-6. PubMed ID: 11477176
[TBL] [Abstract][Full Text] [Related]
2. Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
Malyszko J; Malyszko JS; Hryszko T; Mysliwiec M
Transplant Proc; 2006; 38(1):105-7. PubMed ID: 16504676
[TBL] [Abstract][Full Text] [Related]
3. Thrombin-activatable fibrinolysis inhibitor in kidney transplant recipient with dyslipidemia.
Malyszko J; Malyszko JS; Hryszko T; Mysliwiec M
Transplant Proc; 2003 Sep; 35(6):2219-21. PubMed ID: 14529894
[TBL] [Abstract][Full Text] [Related]
4. Some aspects of hemostasis in kidney transplant recipients maintained on cyclosporine, azathioprine, and prednisone in comparison to patients treated with cyclosporine and prednisone.
Malyszko J; Malyszko JS; Hryszko T; Mysliwiec M
Transplant Proc; 2003 Dec; 35(8):2940-2. PubMed ID: 14697944
[TBL] [Abstract][Full Text] [Related]
5. Fluvastin therapy affects TAFI concentration in kidney transplant recipients.
Malyszko J; Malyszko JS; Mysliwiec M
Transpl Int; 2003 Jan; 16(1):53-7. PubMed ID: 12545342
[TBL] [Abstract][Full Text] [Related]
6. Structural changes in carotid arteries and impairment of fibrinolysis in hemodialyzed and peritoneally dialyzed patients.
Małyszko J; Łebkowska U; Małyszko JS; Myśliwiec M
Med Sci Monit; 2009 Dec; 15(12):CR644-9. PubMed ID: 19946236
[TBL] [Abstract][Full Text] [Related]
7. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Małyszko J; Małyszko JS; Hryszko T; Myśliwiec M
Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223
[TBL] [Abstract][Full Text] [Related]
8. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
Incampo F; Carrieri C; Galasso R; Scaraggi FA; Di Serio F; Woodhams B; Semeraro N; Colucci M
J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension.
Małyszko J; Tymcio J
Pol Arch Med Wewn; 2008; 118(1-2):36-41. PubMed ID: 18405171
[TBL] [Abstract][Full Text] [Related]
10. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
[TBL] [Abstract][Full Text] [Related]
11. [Thrombin activatable fibrinolysis o inhibitor-TAFI- in dialyzed patients with diabetic nephropathy].
Małyszko JS; Małyszko J; Hryszko T; Myśliwiec M
Pol Arch Med Wewn; 2003 Aug; 110(2):843-8. PubMed ID: 14682222
[TBL] [Abstract][Full Text] [Related]
12. Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome.
Malyszko J; Malyszko JS; Mysliwiec M
Blood Coagul Fibrinolysis; 2002 Oct; 13(7):615-21. PubMed ID: 12439147
[TBL] [Abstract][Full Text] [Related]
13. Elucidating the molecular mechanisms of fibrinolytic shutdown after severe injury: The role of thrombin-activatable fibrinolysis inhibitor.
Coleman JR; Moore EE; Kelher MR; Jones K; Cohen MJ; Banerjee A; Silliman CC
J Trauma Acute Care Surg; 2023 Jun; 94(6):857-862. PubMed ID: 36787438
[TBL] [Abstract][Full Text] [Related]
14. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients.
Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Myśliwiec M
Am J Nephrol; 2004; 24(6):624-9. PubMed ID: 15627717
[TBL] [Abstract][Full Text] [Related]
15. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
Watanabe R; Wada H; Watanabe Y; Sakakura M; Nakasaki T; Mori Y; Nishikawa M; Gabazza EC; Nobori T; Shiku H
Thromb Res; 2001 Oct; 104(1):1-6. PubMed ID: 11583733
[TBL] [Abstract][Full Text] [Related]
16. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
Morishima Y; Honda Y
J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
[TBL] [Abstract][Full Text] [Related]
17. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
Kemona-Chetnik I; Kowal K; Kucharewicz I; Pampuch A; Bodzenta-Lukaszyk A
Przegl Lek; 2006; 63(12):1281-5. PubMed ID: 17642140
[TBL] [Abstract][Full Text] [Related]
18. Treatment with everolimus is associated with a procoagulant state.
Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
[TBL] [Abstract][Full Text] [Related]
19. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
20. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Antovic JP; Blombäck M
Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
